Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Latest News

December 14

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study

December 8

Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis

October 30

TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent

All News

Voices of TB

Videos from the Global Health Community

Kenya Launches Child-Friendly TB Medicine

New Childhood TB Medicines Will Help Save Lives

All Voices

Featured Publication

Accessing Improved TB Medicines for Children

  • Click here to download the full report

All Publications

Research Papers

No antimicrobial resistance research agenda without tuberculosis
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
All Papers

For the Press

Press Contact:
Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

View the 2019 Annual Report
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2021 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern